Download Analyst Report on $TSRX HERE-TSRX-SunTrust-Robinson-Humphrey-Feb-12
Tag: trading
Why the latest rally could be a bull trap
This week has been a strange market week for sure. I have held back on picks mainly because I want to see some clarity as I believe we are at a market top, and economic data has peaked out. Furthermore,…
GLOBE NEWSWIRE: Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem’s PLacental eXpanded (PLX) cells orphan drug status…
UPDATED: Cyclacel Pharma: Undervalued With Its Potential Blockbuster Drug
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and…
4 Small Cap Biopharmas With Near-Term Catalysts
To begin this week, I list four biopharma companies I feel have significant catalysts coming up. According to investinganswers.com a catalyst is defined as news or information that changes a pricing trend in a security. Catalysts can drive an investment…
The Obesity Epidemic – EnteroMedics New Treatment Approach
Our focus turns to EnteroMedics (NASDAQ:ETRM), which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics’ approach may be a better solution for people who see little or no…
Weekend Update: $CORT $ATHX $CLSN $BLRX $NEPT + Chart Analysis And Explanation
In this video, I review a couple of charts, and review a couple of my trade calls. Chart analysis and explanation offered. Hope you find the video educational! Scott
Athersys: Upcoming Short Term Catalyst With Promising Longer Term Potential
In 2012, many stem cell stocks experienced fast-paced growth as new and promising research continues to propel the industry forward. Last July, I wrote about Pluristem Therapeutics (PSTI), a bio-therapeutics company engaged in the commercialization of non-personalized cell therapy products…
CORRECTED CHARTS: Chart and commentary on $ATHX and others + Trading Technicals
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. Honoring Dr. King by following his example of looking at a…
Charts and commentary on $ATHX and others + Trading analysis. Honor Dr. King today.
Please excuse the green bed sheet in the background. We were trying different techniques for effects and obviously it did not work! Charts and Commentary on $ATHX and others.. please note; the charts on the right side get cut off…
